💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Chikungunya Virus, Live Attenuated

CHEMBL6068495 Phase 4 Одобрено Vaccine component
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A live attenuated viral vaccine designed to provide immunity against chikungunya virus, which causes a febrile illness characterized by severe joint pain. Administration of the attenuated strain stimulates a durable immune response with both neutralizing antibodies and cellular immunity. It is intended for adults at risk of exposure in endemic areas.

Механизм действия

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

A live attenuated viral vaccine designed to provide immunity against chikungunya virus, which causes a febrile illness characterized by severe joint pain. Administration of the attenuated strain stimulates a durable immune response with both neutralizing antibodies and cellular immunity. It is intended for adults at risk of exposure in endemic areas.

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

Yes, Chikungunya Virus, Live Attenuated is an approved drug. It has reached clinical phase 4. It is classified as a Vaccine component.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068495. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.